PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer
Sandeep Rajput(Washington University in St. Louis), X. Cynthia(Washington University in St. Louis)
Cited by 11
Related Papers
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
|Journal of Clinical Investigation|2012|222
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
|Breast Cancer Research and Treatment|2012|107